H
uman papillomaviruses (HPVs) belong to the large family of double-stranded DNA viruses, comprising over 120 identified HPV types that infect the epithelial cells of the skin or mucosa and cause hyperproliferation, leading to the development of benign papillomas, which occasionally progress to cancerous lesions (1) . HPVs are classified according to their genotype into genera and species, among which the alpha, beta, and gamma genera together contain approximately 90% of the characterized HPV types. The best-studied group of HPVs comprises the mucosal epithelium-infecting alphapapillomaviruses (alphaHPVs), because several high-risk subtypes of these viruses, such as HPV16, HPV18, and HPV31, cause anogenital cancers. Recently, another large group of HPVs, the cutaneous epithelium-infecting betapapillomaviruses (betaHPVs), have gained more attention due to their possible involvement in cutaneous squamous cell carcinoma (SCC). HPV5 and HPV8 are the most prevalent betaHPV types and have been detected in 90% of cutaneous SCCs in epidermodysplasia verruciformis (EV) patients; however, a clear association between betaHPV infections and SCC has not been confirmed (2) (3) (4) (5) .
All HPVs exhibit similar, though not identical, genome structures, organizations, and gene functions. The circular, doublestranded genome of these viruses is approximately 8 kb. The viral genome is transported to the nucleus, where it becomes biologically active and initiates the transcription of viral genes and the production of replication proteins, eventually leading to the replication of the viral genome as an extrachromosomal genetic element. In general, the genome contains eight early and two late protein-coding open reading frames (ORFs), which are all transcribed from the same strand and categorized according to gene specificity into early and late transcripts.
The life cycle of HPV is tightly associated with the differentiation program of keratinocytes, as the virus infects epidermal or mucosal epithelial-proliferating basal cells and establishes a persistent infection; however, virion assembly and maturation occur in terminally differentiated cells (6) . The expression of early regulatory genes occurs in undifferentiated cells in the basal or parabasal layers of the epithelium, whereas viral DNA replication, the expression of capsid proteins, and the assembly of virions occur only in the suprabasal and more differentiated granular layers of the epithelium (7) (8) (9) . The differential expression of viral early and late genes depends on the regulation of viral early and late promoter activity in the basal and suprabasal cells of the epithelium. A noncoding region, referred to as the long control region (LCR), lies between the L1 and E6 genes. The transcription of papillomaviruses is regulated by cis-responsive elements located in the LCR, which contains binding sites for the viral E1 and E2 factors and numerous binding sites for both cellular transcription factors, silencers and repressors, that modulate the activity of enhancers and promoters (10) . Two types of promoters have been identified for alphaHPVs, termed early and late promoters, which direct the expression of HPV ORFs during the early and late phases of the viral life cycle, respectively (9) . The early promoters P97 for HPV16 (11, 12) , P99 for HPV31 (13, 14) , and P102 for HPV18 (15) are located in the LCR upstream of the E6 ORF and direct the expression of E6, E7, and several other early gene products. After induction of the late promoter, productive virus replication is activated, which directs the expression of transcripts beginning from heterogeneous start sites in the E7 ORF, such as P670 in HPV16 (12) , P811 in HPV18 (15) , and P742 in HPV31 (14) .
The RNA mapping data of various HPV-transformed cells suggest that the majority of HPV genome transcripts are polycistronic, with two or more ORFs, and that a variety of coding mRNAs are generated through extensive alternative RNA splicing (http://pave.niaid.nih.gov/#transcriptMaps). One ORF can span two separate exons in the HPV genome, and another ORF can exist in multiple transcripts, initiated at different promoters. These examples demonstrate the complexity of papillomavirus gene expression.
The available information regarding the transcription of betapapillomavirus genes is limited due to the lack of suitable in vitro cell lines enabling the transcription of viral genes and the replication of the viral genome. Haller et al. provided the only report addressing HPV5 differentiation-dependent transcription and alternative splicing, identifying multiple HPV5 transcripts from EV patients via in situ hybridization (16) . Each of the characterized transcripts was spliced at two major splice donor sites: one site was situated in the E6-proximal portion of the LCR region at nucleotide (nt) 4, and the other site was located downstream of the first ATG codon of E1 (nt 982). Furthermore, two major conserved splice acceptor sites were identified: one site was located in the first part of the E4 ORF, at nt 3322, and the other site was located upstream of the E2 ORF, at nt 2676. The early and late promoters have been mapped to transcription start sites (TSSs) at nt P175 and P7535 for HPV8 (17, 18) . Two promoter regions have been implicated in the LCR of HPV5; however, the exact positions of these promoters are unknown and presumed to be similar to those observed in the closely related virus type HPV8 (16) . The HPV5 LCR is only 478 bp long, compared with the Ͼ800-bp LCRs of previously identified alphaHPVs. In addition, the HPV5 LCR does not contain putative binding sites recognized by the transcription enhancer factor TEF-1 and the transcription factor SP-1, which are present in all alphaHPVs (10, 19) . Mucosal HPVs exhibit stronger enhancers in the LCR than HPV5 and HPV8 (10), suggesting that different HPV LCRs also display different capacities to cooperate with cellular factors depending on the tissue types infected. The HPV5 early region is located in the 5= region of the genome and encodes oncoproteins E6 and E7. HPV5 also encodes the viral replication factor and helicase E1 and the viral replication and transcription factor E2. The viral oncoprotein E4 is expressed as a fusion protein with E1. The region between the early and late genes in alphaHPVs is long (300 to 500 bp) and contains the E5 gene; however, in betaHPVs, this region is less than 100 bp (80 bp in HPV5), and the E5 ORF is missing (20) . The late region is located downstream of the early region and encodes the viral major and minor capsid proteins, L1 and L2, respectively (21) .
We demonstrated that the human osteosarcoma cell line U2OS supports the genome replication of alpha-and betaHPVs and is suitable for studying HPV replication and transcription in transient or stable replication mode (22, 23) (A. Männik, G. Kivi, M. Toots, M. Ustav, Jr., E. Ustav, and M. Ustav, unpublished data). In addition, little is known about betaHPV gene expression and the molecular mechanisms of genome replication. Therefore, the objective of the present study was to map the promoter positions and characterize the early transcription and initial replication of HPV5 using transiently transfected U2OS cells and U2OS subclones that stably replicate the HPV5 genome. Using mutated minicircle genomes, we demonstrated for the first time that HPV5 genome replication is completely dependent on the expression of viral early E1 and E2 proteins and that these proteins are critical for the initiation of viral genome replication. However, we were unable to demonstrate the amplification of the betaHPV genome in confluent U2OS cells, as previously shown for alphaHPVs (22) .
We also identified the positions of HPV5 early and late promoters and mapped the viral RNA splice junctions and early polyadenylation cleavage sites (CSs) via 5= rapid amplification of cDNA ends (5=RACE) and 3=RACE and reverse transcription (RT)-PCR analysis. We observed that the HPV5 early transcripts begin at either nt 191 or nt 184, depending on the replication stage and the culture conditions. The late transcripts begin at nt 7640, and the primary promoter area for the generation of transcripts in the HPV5 genome is located in the E7 ORF. Thus, the present study is the first to demonstrate that E1 coding mRNA starts at the main promoter located in the E7 ORF, and we report the mapping of the early polyadenylation cleavage sites to nt 4457 and 4475. We identified a novel promoter area inside E1 ORF at nt 1254, the start site for truncated E1 transcripts and transcripts containing the E8 ORF sequence. The E8 ORF has been described for alphaHPVs (e.g., HPV16 and HPV18 [24, 25] ) and BPV1 (26) , but it has not been described for betaHPVs. Moreover, we showed that, similar to HPV16 and -18, the E8 ORF product, namely, E8^E2C protein, is a repressor of the HPV5 genome replication, which acts via the downregulation of E1 mRNA transcription.
MATERIALS AND METHODS

Cell lines and transfection experiments. U2OS cells obtained from the
American Type Culture Collection (ATCC; number HTB-96) were grown in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum. The cells were transfected via electroporation using a Bio-Rad Gene Pulser II apparatus supplied with a capacitance extender (Bio-Rad Laboratories, Hercules, CA) with settings of 975 F and 220 V. HPV5 U2OS subclone no. 15 cells, carrying a multicopy episomal HPV5 genome (22) , were maintained under either subconfluent conditions, with subculturing to maintain 60 to 70% confluence, or confluent conditions without subculturing for 10 days with regular feeding.
Plasmids. The plasmid pMC-HPV5, for the production of minicircle (mc) genomes, was constructed from the viral genome-containing plasmid pBR322-HPV5 (a kind gift from Frank Stubenrauch and Thomas Iftner) and the minicircle-producing plasmid pMC.BESBX (27) . The viral genome was cleaved from pBR322-HPV5 using SacI. To avoid disrupting the E7 sequence during minicircle formation through the addition of bacterial DNA via attB and attP recombination, we religated the linear HPV5 genome, followed by linearizing with XmaJI, which recognizes a site in L2, and cloning into the XbaI site in pMC.BESBX. The pMC.BESBX vector facilitates the production of the viral genome as a supercoiled miniplasmid, containing only the minimal portion (92 bp) of non-HPV sequences. The minicircle viral genomes were produced in Escherichia coli strain ZYCY10P3S2T (27) according to a previously published protocol for HPV18 minicircles (28) . The HPV5 mutants were engineered using the intermediate plasmid pUC18-HPV5 in which the HPV5 genome was inserted into the SacI site of the pUC18 polylinker. The E1 308-aminoacid (aa) mutant was constructed by linearizing pUC18-HPV5 with OliI and inserting the oligonucleotide (XmaJI) 5=-GACGTGCTCCTAGGCC TCAACAT-3= into this site. The E2 mutant 106 aa was constructed by linearizing pUC18-HPV5 with Eco47III and ligating this plasmid with the oligonucleotide (Bsp119I) 5=-GCTCGCTAGTGTTCGAAGAAGC-3=. The HPV5 mutant genome constructs were verified through sequencing. Thereafter, the mutant genomes were cloned into the pMC.BESPX vector to generate mutant HPV5 covalently closed minicircle genomes.
For cloning the HPV5-E8 mutant, a PCR fragment was generated using an F primer containing the XbaI site (5=-GACTCTAGAGGATCCC CGGGTACCGAGCTC-3=) and an R primer containing the Eco52I site and an ATG-to-ACG mutation in E8 (5=-ATCCGGCCGAGAGTCA ATAGCCGGTACCTCCACCTCAGGAGTAACATCTTCAGCTTCGT TG-3=). The PCR fragment was cloned into pUC18-HPV5 after cleavage with XbaI and Eco52I. The mutated fragment was cleaved from pMC. BESPX-HPV5 with SacI and AdeI. The E8^E1C transcript was cloned into vector pCG by cloning the PCR fragment amplified with the primers (XbaI) 5=-ATCTCTAGAATGAAGCTGAAGATGTTACTCCTGAG GTGGAGGCTTTGGACACAATTAG-3= and (SmaI) 5=-ACACCCGGGT CATAAATGTTCATTAG-3=. The E8^E2C transcript was cloned into vector pCG by cloning the PCR fragment amplified with primers (XbaI) 5=-ATCTCTAGAATGAAGCTGAAGATGTTACTCCTGAGGTG GAGCTCCACGCCTCCAGGGT-3= and (SmaI) 5=-ACACCCGGGTTAA AGACTGTCCAGGT-3=.
DNA extraction and Southern blot analysis. Extrachromosomal DNA was extracted from U2OS cells using the modified Hirt method. The cells were washed three times with phosphate-buffered saline (PBS), and after the liquid was removed, the cells were lysed by adding 0.8 ml of lysis buffer (0.5% SDS, 50 mM Tris [pH 8.0], 10 mM EDTA) dropwise to a monolayer in a 10-cm dish. The cell lysate was incubated for 15 min at room temperature. Subsequently, 200 l of 5 M NaCl was added to the lysate, increasing the NaCl concentration to 1 M, and the lysates were incubated at 4°C overnight. The next day, the chromosomal-membrane complex was precipitated via centrifugation at 12,000 rpm for 20 min at 4°C. The nucleic acids in the supernatant were precipitated by adding 600 l of isopropanol, followed by incubation for 30 min at Ϫ20°C and centrifugation at 12,000 rpm for 15 min at 4°C. The pellet was resuspended in 200 l of proteinase K buffer (20 mM Tris [pH 8.0], 100 mM NaCl, 10 mM EDTA, 0.2% SDS, and 50 g/ml proteinase K) and incubated for 30 min at 56°C. The supernatants were extracted with phenol-chloroform (1:1), and the nucleic acids were precipitated with 2 volumes of 96% ethanol at room temperature. The precipitates were collected at 12,000 rpm for 10 min at 4°C, washed with 70% ethanol, and resuspended in Tris-EDTA (TE) containing 20 g/ml RNase A. The extracted extrachromosomal DNA was cleaved overnight with endonucleases (Thermo Scientific, Waltham, MA). DpnI was added to the cleavage reaction to fragment the nonreplicated input DNA. The fragments were resolved on 0.8% agarose gels, blotted onto a Hybond-N ϩ membrane (GE Healthcare Life Sciences, Pittsburgh, PA), and hybridized with an HPV5-specific probe as previously described (22) .
Total genomic DNA was extracted from the cells using 1 ml of lysis solution (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 10 mM EDTA, and 0.2% SDS) per 10-cm dish. Subsequently, the cell lysates were treated with proteinase K (0.2 g/l) and extracted with phenol-chloroform (1:1), and the nucleic acids were precipitated with 2 volumes of 96% ethanol for 20 min at Ϫ20°C. The precipitates were collected by centrifugation at 12,000 rpm for 10 min at 4°C, resuspended in TE containing 20 g/ml RNase A, and incubated for 24 h at 37°C. Total genomic DNA was precipitated with 96% ethanol, washed with 70% ethanol, and resuspended in TE. The obtained DNA concentrations were measured using a NanoDrop ND1000 spectrophotometer (Thermo Scientific, Waltham, MA).
Cell proliferation assay. U2OS cells were grown as a semiconfluent culture, splitting cells regularly over 2 days, and as a confluent culture, grown on the same plate without splitting for 12 days, with media changed every second day. After 12 days, both U2OS cultures were trypsinized, centrifuged, and plated to the 96-well plate at a density of 3,000 cells per well. The cell proliferation assay was carried out using The CellTiter 96 AQueous One Solution cell proliferation assay kit (Promega, Madison, WI) according to the manufacturer's instructions. The adsorbance was measured at 490 nm at 7 h, 24 h, 48 h, 72 h, and 96 h after plating.
RNA extraction, 5=RACE, 3=RACE, and RT-PCR analyses. Total RNA was extracted from U2OS cells transfected with 1.5 g of the HPV5 minicircle genome 96 h posttransfection or from U2OS subclone no. 15 cells (22) using the FavorPrep blood/cultured cell total RNA purification minikit (Favorgen, Ping-Tung, Taiwan) according to the manufacturer's instructions. The 5=RACE and 3=RACE assays were performed to amplify the ends of the HPV5 transcripts using the FirstChoice RLM-RACE kit (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. Shortly, total RNA was treated with calf intestine alkaline phosphatase (CIP) to remove the free 5=-phosphates from molecules, such as rRNA, fragmented mRNA, tRNA, and contaminating genomic DNA. The cap structure on the intact 5= ends of mRNA was not affected by CIP. The RNA was subsequently treated with tobacco acid pyrophosphatase (TAP) to remove the cap structure from full-length mRNA, leaving a 5=-monophosphate. A 45-base RNA adapter oligonucleotide was ligated to the RNA population using T4 RNA ligase. As the adapter cannot ligate to dephosphorylated RNA because these molecules lack the 5=-phosphate necessary for ligation, only full-length, capped mRNA was ligated and amplified through forward primer binding to the adapter sequence and reverse primer binding to the specific transcript. The HPV5-specific primers used for the amplification of the RACE products were designed in pairs of inner and outer primers. The outer primers were used for the first stage of PCR, and the inner primers were used for nested PCR. The inner primers are shown in Fig. 5 , and all primers are listed in Table 1 . All RACE products were gel purified, cloned (InsTAclone PCR cloning kit; Thermo Scientific, Waltham, MA), transformed into DH5␣, analyzed through colony-PCR, and sequenced as single clones. The RT-PCR was performed using the RevertAid first-strand cDNA synthesis kit (Thermo Scientific, Waltham, MA). The HPV5-E8 transcripts were analyzed through 5=RACE using the SMARTer RACE cDNA amplification kit (Clontech, Mountain View, CA) according to the manufacturer's instructions. For this analysis, the mRNA was extracted from U2OS cells containing wild-type (wt) 1540F  AAAGACTGGGTTGTCTCTGT  E1  3348F  GACAAGCAGACACAAACACCACCTC E2  6251R  CCAGTACTCCCTACACCTAATGGCT  L1  1333F  GCTGAAGATGTTACTCCTGAGGTGG E8  3024R  GACCTTCTGGAGCGCTTCTAAATG  E2  3457R CTCCGTCCGTACCTTCTTCCTCTG E2
a Primer pairs composed of inner and outer primer were used for 5=RACE analyses. Primer number refers to its binding position in the HPV5 genome.
HPV5 or the mutated HPV5-E8 mc genome at 96 h posttransfection using the Dynabeads mRNA DIRECT microkit (Life Technologies, Grand Island, NY).
RESULTS
The HPV5 E1 and E2 proteins are essential for the initiation of viral genome replication in U2OS cells. To identify the viral gene products required for HPV5 genome replication in U2OS cells and define the roles of the E1 and E2 proteins during replication, genomes defective in E1 and E2 protein expression were constructed. Studies have previously shown that the HPV genome, carrying additional sequences linked to the genome, such as a bacterial plasmid, replicate poorly in U2OS cells. Instead of using the laborious and cumbersome procedure of generating a circular HPV5 genome for transfection, which entails cleaving the genome out of the plasmid, purifying the fragment, religating the fragment at low concentrations, followed by another round of purification, we used the bacterial recombination system (27) to generate covalently closed circular HPV5 genomic minicircles. Specifically, mutations were generated in the E1 and E2 ORFs, which encode the putative early viral gene products necessary for the initiation of replication, as demonstrated for other HPVs (29) (30) (31) (32) . We generated two mutant genomes encoding E1 (truncated after 308 aa) and E2 (truncated after 106 aa) by inserting stop codons and the XmaJI (E1) and Bsp119I (E2) recognition sites into the respective ORFs, resulting in frameshifts in the coding sequences of the replication proteins. The HPV5 minicircle genomes, expressing E1 308 and E2 106, were transfected into the U2OS cells. Episomal DNA was extracted at 72, 96, and 120 h after transfection, and viral genome replication was analyzed via Southern blotting. The data presented in Fig. 1A indicate that the wild-type HPV5 minicircle genome replicated well in U2OS cells, and the replication signal increased with time up to 120 h after transfection (Fig. 1A, lanes 1  to 3) ; however, the E1-or E2-defective genomes failed to replicate (Fig. 1A, lanes 4 to 9) . The cotransfection of the E1 and E2 mutant genomes resulted in the clear complementation of the genetic defects, and the replication of both mutant genomes was detected at nearly the same level as that of wild-type HPV5 (Fig. 1A , lanes 10 to 12). Our data clearly show that the replication of the HPV5 genome is completely dependent on the E1 and E2 proteins as viral transfactors.
FIG 1 (A)
Transient replication analysis of the HPV5 wild-type (wt) genome and E1-or E2-defective genomes in U2OS cells. The U2OS cells were transfected with 1.5 g of wt or mutant genomes: E1-defective E1 308 aa and E2-defective E2 106 aa (the number corresponds to the number of translated amino acids in a particular truncated ORF). For the complementation assay, the cells were cotransfected with two mutants (1.5 g of each). Episomal DNA was extracted via Hirt lysis at the indicated time points, 72, 96, and 120 h posttransfection, as shown on the top, and subjected to Southern blotting. Separately transfected genomes were digested with DpnI and linearized using SacI, and cotransfected mutant genomes were digested with DpnI and PscI-XmaJI, generating the linear E2 106 genome and E1 308 genome cut at two sites, to facilitate discrimination between the two cotransfected plasmids. Lanes 1 to 9 represent the analyses of HPV5 wt and mutant genome replication at the indicated time points, lanes 10 to 12 represent the complementation of the genomic defects of the E1-and E2-defective genomes, cotransfected into U2OS cells. Lanes 13 and 14 represent markers for the linear HPV5 mc genome and mutant genome HPV5E1 308 aa digested with the corresponding enzymes. (B) Cell proliferation assay of semiconfluent (split regularly) and confluent U2OS cells (grown on the same plate without splitting for 12 days). After 12 days, both U2OS cultures were plated to the 96-well plate at a density of 3,000 cells per well. The adsorbance was measured at 490 nm at 7 h, 24 h, 48 h, 72 h, and 96 h after plating. (C to E) Viral genome amplification under confluent conditions in U2OS cells. Southern blot analysis of DNA amplification in HPV5 (C), HPV8 (D), and HPV18 (E) mc genome-containing U2OS subclones maintained under confluent culture conditions. The cells were cultured without passaging for the indicated number of days, and total DNA was subsequently extracted. The cell culture medium (IMDM) was changed regularly to ensure the continuous supply of nutrients. Equal amounts of total DNA were linearized with SacI (HPV5 mc genome), BamHI (HPV8 mc genome), and BglI (HPV18) and analyzed via Southern blotting with a genome-specific radiolabeled probe. The replication time points and marker lines are shown.
The HPV5 and HPV8 genomes do not undergo genome amplification in U2OS cells. The generation of HPV5-and HPV8-positive subclones of U2OS cells has been previously described (22) . The HPV mc genome status in the U2OS-positive subclones was studied by one-dimensional (1D) and two-dimensional (2D) replication analyses that confirmed the episomal status of the viral genomes (data not shown), although the viral sequences were also integrated into U2OS chromosome (data not shown). HPV viral particle production is dependent on keratinocyte differentiation and requires specific cell transcription factors to initiate genome amplification, capsid protein expression, and viral particle packaging. We have demonstrated that the cultivation of the alphaHPV-positive U2OS subclones in confluent culture conditions with feeding successfully mimicked the necessary conditions for the induction of viral DNA amplification during the productive stage of infection (22) . However, in contrast to alphaHPVs (22) (Fig. 1E) , of the six HPV5 and HPV8 subclones presented in Fig. 1C and D, no subclones showed genome amplification under confluent conditions for 12 days. In addition, the cell culture remained viable under confluent conditions. We tested cell survival after 12 days in dense culture, and the results showed that confluent cells start to proliferate later than semiconfluent cells, but after 96 h, the viable cell number is equalized (Fig. 1B) . The lack of the betaHPV genome amplification in confluent HPV cells might reflect the lack of certain critical factors for the amplification of the HPV5 and HPV8 genomes in U2OS cells. Similarly, we observed that the HPV5 late promoter was activated in confluent U2OS cells; however, we were unable to identify late polyadenylation cleavage sites for late transcripts.
The E8 ORF is expressed in HPV5 and is involved in the production of E8^E2C as a negative regulator of HPV5 genome replication. In several HPV genomes, E8^E2C is a negative regulator of viral genome replication and downregulates the expression of HPV transcripts. The spliced transcript, in which the E8 ORF is linked to the splice acceptor in the E2 gene, generates the E8^E2C protein as described for BPV1 (26) . The HPV5 E8^E2C comprises a short (10-aa) product of the E8 ORF fused to the C-terminal DNA binding and dimerization domain of the E2 protein. E8^E2C, together with the N-truncated E2 protein, has proved to be a repressor of the full-length E2 protein (26, 33, 34) . The start codon and the splice donor site of the E8 ORF are highly conserved among HPVs. The transcripts corresponding to E8^E2C have also been described for cottontail rabbit papillomavirus (CRPV) and HPV types 1, 11, 16, 18, 31, and 33 (24) (25) (26) (35) (36) (37) (38) (39) but not for any betaHPV. In HPV5, we identified the putative E8 ORF at nt 1328 to 1359. We mutated the E8 start codon ATG to ATC (HPV5-E8 genome) to analyze the function of the E8 ORF in HPV5 replication. Specifically, a huge increase in the replication signal was observed for the mutated genome compared with the wild-type genome (Fig. 2A) . The level of replication was estimated using qPCR and showed that replication was enhanced up to 100 times in 120 h (data not shown), suggesting that E8^E2C is a major repressor of HPV5 gene expression. Similarly, 5=RACE assays were conducted to detect differences in the transcription activity of wt HPV5 and HPV5-E8. The results indicated that most significant differences were associated with E1 transcripts, which were weakly detectable in wt HPV5 but were strongly enhanced in the HPV5-E8 mutant (Fig. 2B, lines 5 to 12) . The E8 ORF-containing transcripts were identified after sequencing the RT-PCR products generated using E8-specific forward primers. This sequencing analysis revealed two differently spliced E8 ORF-containing transcripts (Fig. 2C) . Splice variant 1359/2676 contains 10 aa from the E8 ORF and 32 aa from the E1 C terminus (E8^E1C), while the splice variant 1359/3322 contains 10 aa from the E8 ORF and 315 aa from E2 (E8^E2C) (Fig. 2D) . To evaluate the role of each protein in the regulation of viral genome replication, the E8^E1C and E8^E2C cDNAs were cloned into expression vectors. The cotransfection of increasing amounts of these expression vectors with the HPV5-E8 genome indicated that the expression of the E8^E1C did not affect HPV5-E8 replication (Fig. 2E, lines 1 to  8) , and there was no effect of the control vector (lines 18 to 25). However, a strong effect of the E8 ORF on viral replication was observed with the E8^E2C protein, as the cotransfection of the E8^E2C expression vector efficiently reduced HPV5-E8 replication (Fig. 2E, lanes 9 to 16) .
Mapping of the HPV5 TSSs in U2OS cells. The HPV5 transcription start sites (TSSs) were mapped through 5=RACE analysis using total RNA extracted from U2OS cells transfected with the HPV5 minicircle genome or from U2OS stable subclone no. 15 cells, containing the HPV5 genome (22) . U2OS subclone no. 15 cells were cultivated as a subconfluent culture via regular subculturing at 2-day intervals. These cells were also grown as confluent cultures with regular feeding for 10 days without subculture to promote the expression of late viral genes. The HPV5 transcription start sites (TSS) were determined through cloning and sequencing 630 5=RACE transcripts, resulting in the identification of five promoter regions in the HPV5 genome (see Fig. 5 ).
Using 5=RACE analysis with primer 530, which binds to the E6 ORF, the TSS in the HPV5 LCR region was identified at nt 7640 in confluent U2OS cells (Fig. 3E, line1 ), similar to a late promoter identified for another betaHPV, HPV8, in which an analogous start site was identified in the LCR region at nt 7535 (17) . All of the analyzed transcripts from this promoter were initiated from this single TSS. The use of this promoter region exclusively occurred in U2OS subclone no. 15 cells, maintained as a confluent culture. Initiation at nt 7640 was not detected in transiently transfected U2OS cells and the subconfluent U2OS subclone no. 15 cells.
An HPV5 early TSS was identified at nt 191 in transiently transfected U2OS cells and in the subconfluent culture of the U2OS subclone no. 15 cells (Fig. 3C and D, lines 1 ). This transcription start site, located at the beginning of the E6 ORF, resembles the analogous promoter identified in HPV8 (E6 promoter P175), located in close proximity to the first ATG in E6 (17) . TSSs in this region have also been identified in other HPVs, e.g., P97 of HPV16 (12), P99 of HPV31 (13, 14) , and P102 of HPV18 (15) . The existence of this TSS was also previously suggested after sequencing the HPV5 transcripts from EV patients (16) . Near this TSS, a second TSS was identified at nt 184 in the U2OS subclone grown under confluent conditions (Fig. 3E, line 1) . No other alternative start sites were identified for this promoter region.
Using 5=RACE analysis with primer 530, a third promoter region was identified in transiently transfected U2OS cells at nt 460 in the E6 ORF (Fig. 3C, line 1) . The existence of promoter activity in this region was previously suggested in an in situ hybridization analysis (16) .
An important region containing a strong promoter was identified within the E7 ORF, ranging from nt 708 to nt 915 (P840). This region was previously suggested to be the promoter for the E1 ORF (16) . P840 represents the region most frequently used as a transcription start site in HPV5 transiently expressed in both U2OS cells and U2OS subclone no. 15 cells (Fig. 3C to E) . In the transiently transfected U2OS cells, the most frequently used TSS was located at nt 840 (19.2%), whereas the most frequent TSS was located at nt 811 in the subconfluent U2OS subclone (21.5%) and at nt 888 in the confluent U2OS subclone (17%) (Fig. 4) . Although most alphaHPV early transcripts have E6 and E7 ORFs, the promoter in E7 was reported to be the most frequently used promoter in HPV16. The majority of transcripts observed in intraepithelial neoplasias and invasive cancers were initiated within the HPV16 E7 ORF and therefore did not encode full-length E6 and E7 proteins (40) . Notably, the major promoter involved in HPV5 early gene expression determines the proteins that will mostly be used for regulating the expression of replication proteins, and no proteins with known oncogenic potential, i.e., E6 and E7, are produced from this promoter (Fig. 5) .
We discovered a novel promoter, P1254, inside the E1 ORF, using 5=RACE analysis with primers 1334 and 1971. This promoter region spans from nt 1020 to 1278 and is used as the transcription start site for transcripts of the E8 ORF (Fig. 2B, lines 19 and 20) and truncated E1 protein (Fig. 2B, line 10) . Because the promoter is downregulated through E8 ORF-containing proteins, the transcripts initiated from P1254 were not easily detectable in wt HPV5, but in the E8-deficient mutant genome, these transcripts were replicated to high levels, thereby facilitating the detection of the respective messages.
We also detected viral transcripts initiated from the region spanning from nt 3380 to 3642 in the E2 ORF. However, initiation from this region was rare, ranging from 3% of all sequenced transcripts in the case of the U2OS subclone to 8% in transiently transfected U2OS cells. A promoter area has not previously been described in this region; therefore, the associated transcripts possess unknown functions. Similar areas of promoter activity have been described in the E2 ORF in BPV1 (33), HPV18 (Männik et al., unpublished), and HPV31 (41), which encode E2C, E5, and late genes.
Mapping of the early polyadenylation CSs involved in HPV5 transcription in U2OS cells. mRNA polyadenylation plays an important role in the control of viral and cellular gene expression. The maturation of the 3= end of most pre-RNAs involves the cleavage of the nascent transcript and the addition of a poly(A) tail containing 150 to 200 adenylate residues (21) . The HPV5 early poly(A) signal (PAS) was previously predicted based on analogy with HPV47 (42) , and this signal was localized to the beginning of the L2 ORF at nt 4438. In addition, the late PAS was predicted to lie at nt 7493 (TATAAA), which is the first PA signal after the L1 ORF (http://pave.niaid.nih.gov). In the present study, we attempted to experimentally confirm functional early polyadenylation through mapping the polyadenylation cleavage sites (CSs) using 3=RACE. Total RNA was extracted from both transiently transfected U2OS cells and U2OS cells stably expressing the episomal HPV5 genome, and 3=RACE analysis was conducted using primer Pr3971F, which binds to the end of the E2 ORF. Analysis of subconfluent and confluent conditions. Total RNA was extracted, and 5=RACE was performed using seven reverse primers, as described in Fig. 3 . The resulting RACE products were cloned and sequenced. The relative frequencies of individual transcription start sites are indicated with vertical bars, where the height of each bar represents the percentage of sequenced clones initiated from the TSS in that region. The number above the highest bar represents the position of the most prevalent transcription start site in that region. The linear scheme of the corresponding HPV5 genome region is shown above. the 39 clones obtained from 3=RACE revealed that HPV5 early mRNAs were cleaved at nt 4457 or 4475 (Fig. 3A) . However, certain positions were moderately preferred. In transiently transfected U2OS cells, CS 4457 was more frequently (62%) used compared with the more downstream CS 4475. In contrast, in U2OS subclone no. 15 cells under subconfluent conditions, CS 4475 (54%) was preferred over CS 4457 (33%), and the occasional (13%) usage of CS 4471 was also observed. Similar usage of CSs was detected in cells maintained under confluent conditions: CS 4475 (56%) was more frequently used than CS 4457 (25%) and CS 4454 (19%).
Mapping of HPV5 splice junctions in U2OS cells. We characterized the structure of the viral transcripts expressed during early and stable HPV5 replication in U2OS cells. Total RNA was extracted from U2OS cells transiently transfected with the HPV5 minicircle genome and U2OS subclone no. 15 cells. A total of 630 mRNA transcripts were cloned and analyzed via 5=RACE using the primers depicted in Fig. 5 . The results shown in Fig. 5 revealed a dominant splice donor site for HPV5 at nt 982 (in 304 of the 350 cloned sequences, 87%), consistent with data from EV patients (16) . In addition, the most prevalent splice acceptor sites, at nt 2676 and 3322, were the same as those identified in EV biopsy specimens. An acceptor site was identified at nt 2676 in 24% of the spliced transcripts (79 of 327 clones) and at nt 3322 in 61% of the spliced transcripts (199 of 327 clones).
RNA transcripts A and B are the only sequenced transcripts containing E6 and E7 ORFs (Fig. 3B ) in addition to E1^E4 and E2 transcripts (Fig. 5, RNA A and B) , as previously described (1). These RNA variants were rare compared with the transcripts initiated from P840. The most abundant HPV5 transcript observed in U2OS cells was an mRNA spliced at 982/3322 (Fig. 3C , lines 5 and 6; Fig. 3D, line 5; Fig. 3E , lines 5 and 6) encoding E1^E4 protein (Fig. 5, RNA D) , the major spliced transcript observed with primers 4079 and 4292. The second most abundant transcript was an RNA spliced at 982/2676 (Fig. 3C to E, lines 4) encoding the E2 protein (Fig. 5, RNA C) . The RT-PCR analysis with primer pairs 1333F-3024R and 1540F-3025 also revealed a rare variant of the E2 transcript, spliced at 1884/2676 (Fig. 5, RNA E) . Through 5=RACE analysis, using primers 1466 and 1869 (Fig. 3C,  line 2; Fig. 3D, lines 2 to 3; Fig. 3E , line 2) and primer 2611 (Fig. 2B,  lines 11 and 12 ), we identified a novel mRNA from P840, which encodes the E1 protein (Fig. 5, RNA F) . The E1 coding sequence is included in polycistronic mRNA, which also contains the coding sequence for the E2 protein.
We identified three transcripts starting from the promoter P1254 inside the E1 ORF. RNA G and H are E8-containing transcripts, where the 10-aa-long E8 protein is linked to the protein sequence located 35 aa from the end of E1 (RNA G) or 315 aa from the end of E2 (RNA H). This promoter is also a TSS for the shorter form of E1 (RNA I), lacking an ATG at the N terminus of the protein; however, several downstream methionines can be used as start codons for truncated E1.
We also detected several mRNA variants that employed a splice donor site located at nt 982 or further upstream and rare acceptor sites in the C-terminal portion of E2 (Fig. 3C, line 6; Fig. 3D , line 5; Fig. 3E, lines 5 and 6 ), but these transcripts did not exhibit a proper ORF and encoded only the short 34-aa E2C peptide (Fig. 5 , RNA J to L). Based on the results from both 5=RACE and the RT-PCR analysis, using primers 3348F and 6251R, we identified the HPV5 double-spliced late-region transcript L1 (RNA M), which has previously been described in EV biopsy specimens (16) . The L1 transcript was not detected in transiently transfected U2OS cells using 5=RACE or RT-PCR and was detected only in U2OS subclone no. 15 cells, indicating that this transcript is not expressed during initial viral replication. An HPV5 L2 transcript, spliced at 982/3322-3615/3887 and sequenced from EV patients (16), was not observed in U2OS cells. RNA N was detected using different primer pairs via RT-PCR, representing pre-mRNA (primers not shown).
BPV1 (33, 43) and alphaHPVs (24, 44) express negative regulator proteins (E2C) containing the E2 DNA-binding domain (DBD). A total of 4 ATG codons are present in the first half of the E2 ORF, in frame with E2 and encoding a truncated E2 protein in the HPV5 genome. All of these start codons are located before the E4 ORF, and an additional ATG is present near the end of the E2 ORF at nt 4163. We identified 4 transcripts with TSSs located at nt 2893 (in addition, one TSS was located at nt 2891, and another TSS was located at nt 2894) in confluent U2OS subclone no. 15 cells, potentially encoding an E2C-like repressor protein. Three potential start sites at nt 2945, 3119, and 3140 can be used for the translation of this putative protein. The presence of the putative E2C repressor protein in betaHPVs suggests the existence of a mechanism for the regulation of viral genome replication, similar to the mechanism previously demonstrated for BPV1 and HPV18 (Männik et al., unpublished); however, this hypothesis needs to be experimentally confirmed.
DISCUSSION
U2OS cells provide a useful environment for analyzing human papillomavirus genome replication and viral gene expression. These cells have been used to study the regulation of viral DNA replication during different phases of the alphaHPV life cycle (22) . Furthermore, transcriptional data obtained for HPV18 have shown that viral gene expression in U2OS cells is indeed identical to the gene expression observed during the natural viral infection of keratinocytes (Männik et al., unpublished). Thus, there is no in vitro system for the analysis of the molecular aspects of replication and gene expression for the betaHPV genome. However, because U2OS cells also support the genome replication of betaHPVs (22), we used this system to characterize the betapapillomavirus HPV5 promoter regions and identify the viral transfactors required for HPV5 genome replication.
Specifically, we characterized the critical viral factors involved in the initial replication of the HPV5 genome. A complementation assay using mutated genomes showed that HPV5 genome replication in U2OS cells strictly depends on the expression of the viral E1 and E2 ORFs, similar to other papillomaviruses (29) (30) (31) (32) . We also showed that, similar to BPV1 (26) and alphaHPVs (24) (25) (26) (35) (36) (37) (38) (39) , HPV5 has transcripts from which E8 ORF-containing proteins are translated. We demonstrated that the E8^E2C fusion protein acts as an important negative regulatory factor for gene expression, leading to the suppression and regulation of viral genome replication. The 5=RACE analysis showed that abolishing the HPV5 E8 ORF expression at the protein level after mutating the start codon increased the expression of E1 ORF-containing transcripts. These results are consistent with HPV31-related data showing that the E8 domain confers long-distance transcriptional repression activity on E8^E2C, the master repressor of viral gene expression (45) .
Analysis of the HPV5 TSSs revealed that the viral early promoter is located at nt 191 upstream of the E6 gene in the case of initial or stable replication. In contrast, this TSS is located at nt 184 when the viral genome is maintained in confluent cells. This early promoter contains a canonical TATA box (TATAA) at 24 bp upstream of TSS 191. Haller et al. also identified the promoter upstream of the E6 gene in a study examining biopsy specimens from the benign lesions of EV patients via cDNA analysis and in situ hybridization (16) . The promoter regions located upstream of the E6 ORF are common among papillomaviruses, e.g., HPV8 P175 (17), HPV16 P97 (12), HPV31 P99 (13, 14) , and HPV18 P102 (15) . Interestingly, these early start sites in HPV5 lack heterogeneity, with all transcripts beginning at the same nucleotide. According to data regarding the transcription of the alphaHPVs HPV16 (12) and HPV18 (15) , the broad distribution of TSSs is common. Mucosal and cutaneous epithelia have been shown to express different proteins (46) ; therefore, it is conceivable that cutaneous and mucosal HPVs are exposed to different transcriptional environments. The mucosal epithelia are located at sites ranging from oral to anogenital regions, which provide slightly different microenvironments for HPV replication. While cutaneous tissue is considered an immune-privileged site, the mucosal epithelia are much more actively surveyed by the immune system and exposed to IgA (47) . It is possible that the skin represents a more homogenous environment for viruses compared with the complexity of the mucosal epithelia. These factors might result in greater heterogeneity at the transcriptional and translational levels, leading to a larger number of splicing variants in alphaHPVs than in betaHPVs.
The P184/191 TSS enables the transcription of the E6 and E7 genes, represented in Fig. 5 as transcripts A and B, respectively. The exact functions of the betapapillomavirus E6 and E7 ORF products remain poorly understood. Compared with high-risk mucosal HPV types, E6 expression among cutaneous HPVs is differentially regulated through wt p53, and cutaneous HPV E6 proteins do not induce the proteasome-mediated degradation of p53 or PDZ domain proteins (48, 49) . However, E6 gene expression from several cutaneous HPV types protects keratinocytes from UV-B-induced apoptosis (50, 51) by mediating the degradation or reduction of the levels of the proapoptotic Bak protein, thereby preventing the release of proapoptotic factors from the mitochondria (52, 53) . However, this finding was not confirmed when E6/E7 was expressed in HaCat keratinocytes (54) . It has been demonstrated that wt p53 induces the downregulation of E6 from HPV5, HPV20, and HPV38 (55) , supporting the notion of a role for E6 in oncogenesis. In organotypic cultures of betaHPVs, E6 and E7 cause a delay in differentiation and altered keratinocyte growth (56, 57) .
A second early promoter region lies within the E7 ORF at nt 840. This promoter differs from P191 in the great heterogeneity of transcription initiation observed in this region, with the dominant TSS ranging from nt 811, in the subconfluent subclone, to nt 888, in confluent culture. The differences observed in major TSS usage reflect how the complex viral transcription pattern is associated with the differentiation program of host cells, mimicked by growing cultured cells under different conditions. Sequences upstream of P840 contain a putative TATA box sequence (TTATA) at nt 817. The clustering of scattered TSSs in the E7 ORF has been shown during the productive infection of the alphaHPV HPV18 in keratinocytes (15) and in U2OS cells (Männik et al., unpublished) . Promoter activity at the E7 ORF was also previously demonstrated in HPV16 (12, 58) and HPV31 (14) .
A third early promoter, P460, in the E6 coding region, was observed only in transiently transfected U2OS cells and is analogous to the putative promoter upstream of the E7 ORF in HPV8 (18) . This promoter might regulate the transcription of E7 and downstream proteins. P460 is used only during the beginning of the viral infection because the relevance of this promoter diminishes when the virus switches to stable replication and the viral copy number is high in the host cell. E7 immortalizes primary human keratinocytes, and HPV38 E7 has been shown to promote keratinocyte proliferation by negatively regulating the formation of actin cytoskeleton fibers and inhibiting actin cytoskeleton remodeling (59) .
We also mapped the new promoter, P1254, which lies in the E1 ORF and is used for the transcription of repressor protein and truncated E1 protein. Similar to P840, P1254 is a promoter region with several TSSs covering the short region in the beginning of E1. The HPV5 late promoter was mapped to nt 7640, and similar to P184/191, this late promoter exhibits a single TSS. This promoter position resembles that of the late promoter P7535, identified in another betaHPV type, HPV8 (17) , and containing a TATA box (AATATA) upstream of the identified TSS. Transcripts that begin at P7640 were observed only in confluent U2OS subclone no. 15 cells. The activation of transcription from the late promoter is likely influenced by dense culture conditions, but transcripts from this promoter were too rare to successfully sequence late PAS. We concluded that the U2OS cell line might lack the necessary transcription factors and therefore does not generate a suitable environment for enabling strong betaHPV genome amplification. In addition, there are no data demonstrating betaHPV amplification in the upper layers of the differentiating epithelia in betaHPVpositive tumors. These data might therefore reflect a particular feature of cutaneous papillomaviruses and suggest that the late amplification phase is typically absent in the life cycle of betaHPVs.
Polyadenylation is an important step in mRNA maturation and controls viral gene expression. All RNA transcripts lacking a tail comprising 100 to 200 adenosine residues are degraded. During the early stages of the viral life cycle, all viral pre-mRNAs are polyadenylated almost exclusively at the early polyadenylation site (PAS) (21) . The early and late polyadenylation signals for HPV5 have not been previously mapped, but they were determined based on analogy with the related virus HPV47 (42) . Here, we experimentally confirmed that the polyadenylation signal (AAUAAA) located in the L2 ORF of HPV5 (nt 4438) directs the cleavage of early viral mRNAs at nt 4457 and 4475. The cleavage site at nt 4475 was slightly more frequently used in U2OS subclone no. 15 cells (54% in subconfluent and 60% in confluent cells) than nt 4457, whereas in transiently expressed HPV5, the cleavage site at nt 4457 was used in 62% of all transcripts, and the site at nt 4475 was used in 38% of all transcripts. The HPV5 cell line contained a small number of transcripts with the minor CS at nt 4471 (13%) in subconfluent cultures and at nt 4454 (19%) in confluent cultures. A putative late PAS is predicted at nt 7493, which contains a TATAAA sequence at 25 bp downstream of the 3= end of the L1 ORF (http://pave.niaid.nih.gov). We detected only one spliced late L1 gene transcript and no spliced L2 transcripts. The data suggest that the U2OS cell line lacks certain factors needed for the stability of the late mRNAs and/or the switch to late polyadenylation of HPV5.
Unlike the high-risk alphaHPVs, the betaHPVs generally remain episomal inside the cell (60), reflecting major differences between the behavior of alpha-and betaHPVs during infection and propagation. Transcriptome sequencing from cutaneous SCCs has also demonstrated low viral copy numbers for betaHPVs and a lack of transcripts potentially encoding oncogenic proteins, in contrast to alphaHPVs, which exhibit much higher viral copy numbers per cell (61) . It is possible that unlike alphaHPVs, the betaHPV genome is generally not as strongly amplified during the last step of infection due to weaker enhancers in the LCR and the absence of important transcription factor recognition sites, such as SP-1 and TEF-1.
Polyadenylation and splicing are cotranscriptional processes. Mapping of the splice junctions in U2OS cells transiently expressing or stably maintaining HPV5 confirmed the major and minor donor and acceptor sites, as previously described (16) . Using multiple 5=RACE primers that bind to the HPV5 early region, we detected transcripts that exhibit primarily a splice donor site at nt 982 at the beginning of the E1 ORF. This site was also a major donor site in an analysis of skin carcinomas from EV patients (16) and is highly conserved among papillomaviruses. The major splice acceptor sites for HPV5 were observed at nt 2676 and 3322, confirming the findings of a previous study (16) . Transcripts beginning with E6 and E7 ORFs (RNA A and B, Fig. 5 ) and transcripts beginning from the promoter within E7 and spliced at nt 2676 and 3322 (RNA C and D, Fig. 5 ) also formed the majority of the mRNA transcripts identified from EV patient skin samples (16) , demonstrating the compatibility of the U2OS cell line as a model system for studying betaHPV replication. Thus, the results of the present study have provided the first demonstration that the E1 transcript begins at promoter area P840 within the E7 ORF. In addition to the E8 ORF, containing transcript E8^E2C (discussed above), transcript E8^E1C was also identified. E8^E1C potentially encodes a protein containing the E8 ORF product (10 aa) fused with the C terminus of the E1 protein. Similar transcripts have been previously reported for HPV11 in laryngeal papilloma (62) and in rat cell lines transfected with type 47 human papillomavirus DNA (42) . The overexpression of E8^E1C does not affect HPV5-E8 genome replication; however, the function and the role of this protein variant remain to be studied.
Collectively, our data show that the human osteosarcoma cell line U2OS provides a novel platform for the analysis of the replication and gene expression of betaHPVs, such as HPV5, in the context of the actual viral genome. This study defined the role of viral gene products at different stages of viral replication, providing further insight into the regulation of gene expression in these viruses.
